WO2019141263A1 - 一种广谱抗肠道病毒的多肽及其应用 - Google Patents

一种广谱抗肠道病毒的多肽及其应用 Download PDF

Info

Publication number
WO2019141263A1
WO2019141263A1 PCT/CN2019/072455 CN2019072455W WO2019141263A1 WO 2019141263 A1 WO2019141263 A1 WO 2019141263A1 CN 2019072455 W CN2019072455 W CN 2019072455W WO 2019141263 A1 WO2019141263 A1 WO 2019141263A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
sequence
virus
cells
amino acid
Prior art date
Application number
PCT/CN2019/072455
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
周溪
陆路
方媛
姜世勃
刘泽众
秦成峰
邱洋
穆敬芳
Original Assignee
中国科学院武汉病毒研究所
复旦大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中国科学院武汉病毒研究所, 复旦大学 filed Critical 中国科学院武汉病毒研究所
Priority to JP2020560535A priority Critical patent/JP7252575B2/ja
Priority to US16/963,196 priority patent/US11999806B2/en
Priority to CN201980005805.6A priority patent/CN112261946B/zh
Priority to AU2019208788A priority patent/AU2019208788B2/en
Publication of WO2019141263A1 publication Critical patent/WO2019141263A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to the field of biomedicine, in particular to a broad spectrum anti-enteric virus polypeptide and application thereof.
  • Enterovirus is a class of sense single-stranded RNA viruses belonging to the genus Picornaviridae enterovirus, including human enterovirus (EV) and coxsackie A (Coxsackie A). Virus, CVA), Coxsackie B virus (CVB), Echovirus, Rhinovirus, Poliovirus, and the like. Enterovirus infections are widely distributed throughout the world, with complex clinical manifestations ranging from mild hypothermia, fatigue, respiratory diseases, to herpetic angina, hand, foot and mouth disease, and severe aseptic meningitis, myocarditis, encephalitis, Polio and so on. There is currently no symptomatic drug for effective treatment or protection against enterovirus infection.
  • Herpetic angina is mainly caused by coxsackievirus group A (CVA2), CVA4, CVA6, CVA9, CVA16, CVA22, and group B type 1 (CVB1), CVB2, CVB3, CVB4, CVB5.
  • CVA2 coxsackievirus group A
  • CVA4 CVA6, CVA9, CVA16, CVA22
  • group B type 1 CVB1
  • CVB2 group B type 1
  • the heat stroke is about 2 to 4 days.
  • Older children can complain of sore throat and can affect swallowing. Infants and young children are characterized by hooliganism, refusal to eat, and irritability.
  • Sometimes with headache, abdominal pain or myalgia the 25% of children under 5 years of age can be accompanied by vomiting.
  • Typical symptoms appear in the pharynx. It is characterized by pharyngeal congestion. There are several (1 to 2, as many as 10) small (1 to 2 mm in diameter) gray-white herpes in the oral mucosa within 2 days of onset, surrounded by redness. After 2 to 3 days, the redness increased and the herpes ruptured to form a yellow ulcer. This mucosal rash is more common in the anterior column of the tonsils, but also in the soft palate, uvula, and tonsils, but does not involve the gums and buccal mucosa. The course of the disease is usually 4 to 6 days, occasionally extended to 2 weeks.
  • Hand, foot and mouth disease is mainly caused by enterovirus 71 (EV71), CVA6, CVA8, CVA10, CVA16, CVB3 and CVB5.
  • EV71 enterovirus 71
  • the common clinical manifestations of hand, foot and mouth disease are acute fever, mouth pain, anorexia, scattered herpes or ulcers in the oral mucosa, and are located in the tongue, buccal mucosa, and hard, etc., and can also affect soft palate, gums, tonsils, and pharynx.
  • the number of rashes is as small as a few dozen. No signs left after disappearing, no pigmentation. Some children with hand, foot and mouth disease have herpes angina as the first symptom, and then a red rash can appear in the palm, sole, buttocks and other parts. When the course of disease develops rapidly, a small number of children can develop from severe hand, foot and mouth disease to severe aseptic meningitis and encephalitis. It is characterized by fever, headache, nausea, vomiting, meningeal irritation, body temperature fluctuations, most cases of low fever, can also be as high as 40 ° C or more, often bimodal fever in the course of the disease. Other symptoms such as sore throat, muscle soreness, rash, photophobia, diarrhea, swollen lymph nodes, etc., mild cases such as mild paralysis.
  • Myocarditis is mainly caused by CVB1-61 and Echovirus.
  • the clinical manifestations of patients with viral myocarditis depend on the extent and location of the disease, and mild cases can be asymptomatic. In severe cases, heart failure, cardiogenic shock, and sudden death can occur. Patients often have a history of upper respiratory tract or intestinal infection 1 to 3 weeks before onset, which is characterized by fever, body aches, sore throat, burnout, nausea, vomiting, diarrhea, etc., followed by palpitations, chest tightness, chest pain or pain in the precordial area. Dizziness, difficulty breathing, edema, and even Adams-Stokes syndrome; very few patients develop heart failure or cardiogenic shock.
  • the enterovirus is a sense single-stranded RNA virus with a genome size of approximately 7.5 kb and a large ORF encoding a polyprotein.
  • the polyprotein is further hydrolyzed into four structural proteins (VP1-VP4) and seven non-structural proteins (2A-2C and 3A-3D).
  • the 3A protein is a very conserved non-structural protein in enteroviruses (including EV71, CVA, and CVB, etc.), which exists as a homodimer and localizes to the cell's inner membrane, replicating the virus and regulating the host's natural immunity. Play an important role.
  • RNA interference RNA interference
  • dsRNA virus-derived double-stranded RNA
  • AGO Argonaute
  • RISC RNA-induced silencing complexes
  • the present invention provides polypeptides and uses thereof.
  • the present invention provides the following technical solutions:
  • the present invention provides the use of Enterovirus RNA suppressing protein (ERSP) as a target for the preparation of a medicament for preventing and/or treating a viral disease.
  • ESP Enterovirus RNA suppressing protein
  • the invention also provides for the use of a polypeptide for the preparation of an inhibitor that targets ERSP; the function of the ERSP is inhibited by the polypeptide, and the viral nucleic acid is cleaved by Dicer to produce a vsiRNA.
  • the invention also provides the use of a polypeptide for the preparation of a medicament for the prevention and treatment of viral diseases.
  • the ERSP is enterovirus non-structural protein 3A.
  • the enterovirus is a Piporaviridae enterovirus genus, including Enterovirus (EV) and Coxsackie A virus (Coxsackie A virus). , CVA), Coxsackie B virus (CVB), Echovirus, Rhinovirus, Poliovirus, and the like.
  • EV Enterovirus
  • COxsackie A virus Coxsackie A virus
  • CVA Coxsackie B virus
  • Echovirus Rhinovirus
  • Poliovirus Poliovirus
  • the disease is hand, foot and mouth disease, myocarditis, herpetic angina, aseptic meningitis, encephalitis, viral influenza, and the like caused by the virus.
  • the amino acid sequence of the polypeptide comprises CR, CK and/or DLL.
  • polypeptide has the following sequence:
  • X1 is selected from the group consisting of isoleucine (I);
  • X2 selects serine (S) or alanine (A);
  • X3 is selected from alanine (A) or lysine (K) or glutamine (Q) or arginine (R) or serine (S) or cysteine (C);
  • X4 is selected from serine (S) or alanine (A);
  • X5 is selected from the group consisting of glutamic acid (E) or glutamine (Q);
  • X6 is selected from arginine (R) or lysine (K);
  • Amino acid as used herein includes a natural amino acid or a non-natural amino acid. Amino acid types well known to those skilled in the art are within the scope of the present invention.
  • the sequence as described in I is as set forth in any one of SEQ ID Nos. 1 to 14, but does not include the sequence of the transmembrane peptide and the sequence of the linker peptide.
  • the invention also provides polypeptides capable of inhibiting the activity of ERSP.
  • the amino acid sequence of the polypeptide comprises CR, CK and/or DLL.
  • the amino acid sequence of the polypeptide comprises YCR and/or YCK.
  • polypeptide has the following sequence:
  • X1 is selected from the group consisting of isoleucine (I);
  • X2 selects serine (S) or alanine (A);
  • X3 is selected from alanine (A) or lysine (K) or glutamine (Q) or arginine (R) or serine (S) or cysteine (C);
  • X4 is selected from serine (S) or alanine (A);
  • X5 is selected from the group consisting of glutamic acid (E) or glutamine (Q);
  • X6 is selected from arginine (R) or lysine (K);
  • the polypeptide is as described in any one of SEQ ID Nos. 1 to 14 as described in I, but does not include the sequence of the transmembrane peptide and the sequence of the linker peptide.
  • the present invention also provides a nucleic acid encoding a nucleotide sequence of the polypeptide.
  • the invention also provides recombinant vectors, including the nucleic acids described.
  • the invention also provides host cells, including the recombinant vectors.
  • the invention also provides medicaments, including the polypeptides and pharmaceutically acceptable excipients.
  • the invention also provides a vaccine comprising the polypeptide and a pharmaceutically acceptable excipient.
  • the invention also provides a method of treating an enterovirus-infected disease, taking and/or injecting the medicament.
  • the injection is intramuscular, intraperitoneal or intravenous.
  • the present invention also provides a method of preventing an enterovirus-infected disease by inoculating the vaccine.
  • prevention refers to various means or measures for preventing the occurrence or development of a disease, including medical, physical or chemical means, to prevent and reduce diseases before a disease which is not recognized by clinical standards. The occurrence or development of a symptom.
  • treatment refers to the prevention, suppression, alleviation, amelioration, mitigation, cessation, delay or reversal of the progression or progression of a disease in order to prevent and reduce the occurrence or progression of the disease.
  • Various indicators of disease, disorder, or pathological state at the time of administration and/or administration include alleviating or reducing symptoms or complications, or curing or eliminating a disease, disorder, or condition.
  • drug means a single compound, a composition formed by a plurality of compounds, or a composition or a preparation having a single compound as a main active ingredient, which can be used for preventing or treating a certain disease, It also refers to a composition or formulation from which a plurality of compounds are the active ingredients.
  • “Drug” should be understood to refer not only to the products approved and approved for production by the administrative agencies established by the laws of a country, but also to the inclusion of a single compound as an active ingredient in order to obtain approval and approval of production. Various forms of matter. "Formation” is understood to mean obtained by chemical synthesis, biotransformation or purchase.
  • the present invention also provides an inhibitor of enterovirus type 71, wherein the inhibitor is polypeptide P2, and the amino acid sequence of P2 is represented by SEQ ID NO.
  • the present invention also provides a recombinant prepared by the inhibitor, which is 3A-TAT-EP, 3A-EP-DRI or 3A-EP-PEG4-PA, and the amino acid of the 3A-TAT-EP
  • the amino acid sequence of the 3A-EP-PEG4-PA represented by SEQ ID NO. 4 and the non-natural amino acid sequence of 3A-EP-DRI shown in SEQ ID NO. 3 is represented by SEQ ID NO.
  • the invention also provides the use of said inhibitor or said engineered body for the preparation of an enterovirus inhibitor.
  • RNA interference is an antiviral immune mechanism.
  • double-stranded RNA generated by viral RNA replication is recognized by the host Dicer protein and cleaved into small interfering RNA (siRNA).
  • siRNA small interfering RNA
  • vsiRNAs virus-derived small interfering RNAs
  • the non-structural protein 3A of EV71 can bind to viral double-stranded RNA to prevent Dicer from cleavage and inhibit the production of small interfering RNA derived from vsiRNA virus, thereby achieving the purpose of escape RNA interference against anti-virus immunity.
  • the polypeptides provided by the invention have an efficient, broad spectrum antiviral activity. This provides a new strategy for the prevention and control of EV71 virus, CVA16 virus, CVA6 virus, CVB3 virus and CVB5 virus, and also accelerates the polypeptides against human enterovirus 71, CVA16, CVB3 and CVB5 viruses.
  • the development of molecular drugs provides a new theoretical basis.
  • Figure 1 shows the results of detecting the ability of polypeptide P2 to cross the cell membrane into the cytosol by fluorescent labeling
  • Figure 2 shows the cytotoxicity results of the polypeptide P2 as determined by CCK-8;
  • Figure 3 shows the results of antiviral efficacy of polypeptide P2 in RD cells
  • FIG. 4 shows that polypeptide P2 has an inhibitory effect on viruses in various cells
  • Figure 5 shows the antiviral effect of the polypeptide modified with the polypeptide P2
  • Figure 6 shows the antiviral effects of polypeptides 3A-EP-DRI and 3A-TAT-EP;
  • Figure 7 shows the results of detecting the antiviral activity of polypeptide P1 against EV71 in mice
  • Figure 8 shows the results of detecting the antiviral activity of the polypeptide P1 against CVA16 in mice
  • Figure 9 shows the results of anti-EV71 effect detection of polypeptide CR in RD cells
  • Figure 10 shows the results of antiviral activity of polypeptide CR against EV71 in mice
  • Figure 11 shows the results of antiviral activity of polypeptide CR against CVA16 in mice
  • Figure 12 shows the results of body weight measurement of toxicity evaluation of polypeptide ER-DRI in mice
  • Figure 13 shows the HE staining results of toxicity evaluation of polypeptide ER-DRI in mice
  • Figure 14 shows the results of transmembrane efficiency detection of polypeptide P1 in RD cells
  • Figure 15 shows the results of cytotoxicity experiments of polypeptide P1
  • Figure 16 shows the results of cytotoxicity experiments of the polypeptide 3A-TAT-EP
  • Figure 17 shows the results of cytotoxicity experiments of polypeptides 3A-EP-DRI and 3A-EP-PEG4-PA;
  • Figure 18 shows the results of detection of antiviral effects of the polypeptides EP-PA, EP-CHOL, 3A-EP-DRI and 3A-EP-PEG4-PA;
  • Figure 19 shows the results of toxicity tests of ER-DRI and ER in RD cells
  • Figure 20 shows the results of anti-EV71 virus detection of ER-DRI and ER in RD cells.
  • Figure 21 shows the results of detecting the antiviral activity of the polypeptide ER-DRI against EV71 in mice
  • Figure 22 shows the results of detection of anti-CVA16 virus effects of polypeptides P2, ER, ER-DRI, R8 and TAT;
  • Figure 23 shows the results of toxicity tests of polypeptides BP8, BP10 and BP15 in RD cells
  • Figure 24 shows the results of toxicity tests of polypeptides BP8, BP10 and BP15 in Vero cells
  • Figure 25 shows the results of anti-CVB5 effect detection of polypeptides BP8, BP10 and BP15 in RD cells
  • Figure 26 shows the results of anti-CVB3 effect detection of polypeptide BP8 in Vero cells
  • Figure 27 shows the results of anti-CVB5 effect detection of polypeptide BP8 in mice
  • Figure 28 shows the results of anti-CVA6 effect detection of polypeptide ER-DRI in Vero cells.
  • the invention discloses a polypeptide and an application thereof, and those skilled in the art can learn from the contents of the paper and appropriately improve the process parameters. It is to be understood that all such alternatives and modifications are obvious to those skilled in the art and are considered to be included in the present invention.
  • the method and the application of the present invention have been described by the preferred embodiments, and it is obvious that the method and application described herein may be modified or appropriately modified and combined without departing from the scope of the present invention. The technique of the present invention is applied.
  • the EV713A protein contains 86 amino acid residues. 3A has the ability to dimerize, and its dimerization plays a key role in the proper functioning of 3A.
  • the applicant designed the polypeptide P2 (SEQ ID NO. 2) with the EP polypeptide as the core sequence in order to allow the inhibitor to penetrate the cell membrane and enter the cell to inhibit the virus. It is capable of competitively interacting with ⁇ 1, thereby preventing 3A dimerization, inhibiting the anti-innate immunity of 3A, and finally achieving anti-viral purposes.
  • the modified bodies are: 3A-TAT-EP, 3A-EP-DRI and 3A-EP-PEG4-PA; the amino acid sequence of the 3A-TAT-EP is shown in SEQ ID NO. 3, 3A-EP The amino acid sequence of the -DRI is represented by SEQ ID NO. 4, and the amino acid sequence of 3A-EP-PEG4-PA is represented by SEQ ID NO.
  • an inhibitor of enterovirus type 71 comprising preparing an enterovirus 71 type inhibitor using the P2 and P2 recombinants provided by the present invention, or using the P2 and P2 recombinants provided by the present invention and other effective Together with the ingredients, an inhibitor of enterovirus type 71 was prepared.
  • the protection of the present invention also includes an inhibitor which inhibits the activity of EV71 after replacing the different transmembrane sequences, or performing polypeptide modification, or designing and modifying non-natural amino acids according to the P2 polypeptide.
  • Enterovirus 3A is a highly potent ERSP that binds to viral dsRNA to prevent Dicer from cleavage, inhibits the production of viral-derived vsiRNA, and resists host RNAi antiviral immunity.
  • polypeptide and the derivative thereof according to the invention are capable of inhibiting the antiviral immunity of enterovirus 3A, and are an emerging therapeutic drug for EV71, which is important for targeting new targets and fighting against viral resistance.
  • the present invention has the following advantages:
  • the P2 series of polypeptides have potent antiviral activity. This will provide a new strategy for the prevention and control of enterovirus, and also provide a new theoretical basis for accelerating the development of anti-human enterovirus polypeptide small molecule drugs. And the clear anti-viral mechanism of the P2 series of peptides can ensure the safety of its application and the clarity of the optimization route, which is convenient for further development in the future.
  • polypeptides involved in the present invention are shown in Table 1:
  • RRRRRRRR (R8) and YGRKKRRQRRR (TAT) are polypeptides in the polypeptide sequence
  • GSG is a linker peptide
  • the amino acid sequence of each polypeptide is removed from the sequence of the transmembrane peptide and the linker peptide as a core sequence.
  • the polypeptides in various embodiments of the invention were provided with a negative control demonstrating that the core sequences of the polypeptides provided herein have corresponding antiviral effects.
  • polypeptides and the materials and reagents used in the application of the present invention are commercially available.
  • MEM medium (Thermo), serum (Gibco) was purchased from Infineon, Inc., immunofluorescent plate (NEST) was purchased from the promoter company, PBS, DAPI, and paraformaldehyde was purchased from Diyue Innovation Co., Ltd.
  • the polypeptide P2 was synthesized by Nanjing Jinsirui Co., Ltd., and its sequence is shown in SEQ ID NO.
  • the experiment was divided into two groups. In order to avoid the influence of the addition of EV71 virus on the entry of the polypeptide into the cells, one group of experiments added EV71 virus and then added the polypeptide P2, and the other group added the virus without adding the virus, and each group was made a negative control.
  • the immunofluorescence steps are as follows:
  • the transmembrane efficiency in RD cells was examined using a fluorescently labeled (FITC) polypeptide.
  • FITC fluorescently labeled
  • CCK-8 Reagent (MCE) was purchased from a startup subsidiary.
  • Peptide P2 not only inhibits the virus in the process of antiviral, but also ensures that it is not toxic to cells. Therefore, this indicator was tested by a cytotoxicity test, and the cells which were not treated were used as a control group.
  • a 96-well cell plate was plated with RD cells at 100 ⁇ l per well.
  • the MEM medium containing 10% serum is replaced with MEM medium containing 2% serum, and a certain concentration gradient of polypeptide P2 is added to make the final P2 concentration in the well.
  • concentration gradient of polypeptide P2 was added to make the final P2 concentration in the well. They were 0.01 ⁇ M, 0.1 ⁇ M, 1 ⁇ M, 10 ⁇ M, and 100 ⁇ M, respectively.
  • the results are shown in Fig. 2 and Table 2.
  • the cell viability of the untreated cells was 100%. There was no significant difference between the cell viability and the control group (untreated cells) after adding 100 ⁇ M of the polypeptide, which proved that the polypeptide P2 used in this study was 100 ⁇ M. It is not toxic to cells.
  • RNA extraction kit (Omega), 24-well plate, 100mm dish, 50ml syringe were purchased from Diyue Innovation Co., Ltd., 0.22 ⁇ m filter (Millipore) was purchased from the company, and the One step qRT-PCR kit (Takara) was purchased. Since the company, the water used in the extraction of RNA and qRT-PCR was DEPC water, and the whole experiment was carried out in the RNase Free environment.
  • One step qRT-PCR was performed by taking 100 ⁇ l of virus-extracted RNA and previously extracted known titer of viral RNA, and the virus titer was measured.
  • polypeptides were added at a final concentration of 0.01 ⁇ M, 0.1 ⁇ M, 1 ⁇ M, 10 ⁇ M, and 50 ⁇ M, respectively.
  • RD cells supplemented with the R8 transmembrane peptide (sequence: RRRRRRRR) were used as a negative control.
  • the results are shown in Fig. 3 and Table 3.
  • the amount of viral RNA in the experimental group added with R8 by EV71 virus was 100%.
  • the amount of virus decreased with the increase of the polypeptide concentration, and the polypeptide concentration was 50 ⁇ M.
  • the amount of virus decreased to about 4%, which proved that the polypeptide P2 has a good antiviral effect.
  • the virus titer was detected by qRT-PCR method, and the IC 50 value of P2 was determined to be 6.372 ⁇ M; in combination with FIG. 2, the polypeptide P2 was at 100 ⁇ M. There is no cytotoxicity inside, which proves that the peptide has a good antiviral effect under the premise of safe medication.
  • RD cells were used to detect the antiviral effect of polypeptide P2.
  • a 24-well plate was plated with 293T cells, Vero cells, and Huh7.5 cells.
  • polypeptide P2 was added to different cells at a final concentration of 0.01 ⁇ M, 0.1 ⁇ M, 1 ⁇ M, 10 ⁇ M, and 50 ⁇ M, respectively.
  • polypeptide P2 can exert significant antiviral effects in both RD cells, 293T cells, Vero cells and huh7.5 cells.
  • the IC 50 values measured for 293T cells, Vero cells, and H ⁇ h7.5 cells were 9.677 ⁇ M, 1.958 ⁇ M, and 1.842 ⁇ M, respectively.
  • Example 5 Effect of the modified polypeptide of polypeptide P2 on the antiviral effect
  • Polypeptides 3A-TAT-EP shown in SEQ ID NO. 3
  • 3A-EP-DRI shown in SEQ ID NO. 4
  • 3A-EP-PEG4-PA shown in SEQ ID NO. 5
  • a 24-well plate was plated with 293T cells.
  • polypeptides P2, 3A-TAT-EP, 3A-EP-DRI and 3A-EP-PEG-PA were added at a final concentration of 0.01 ⁇ M, 0.1 ⁇ M, 1 ⁇ M, and 10 ⁇ M, respectively.
  • RD cells with good growth conditions were plated in 96-well plates at 1 ⁇ 10 4 per well, and cultured for 24 hours at 37 ° C and 5% CO 2 .
  • the diluted virus was added to the above wells, 100 ⁇ L per well, and the drug-free virus-free wells and the drug-free virus-free wells were set as controls, respectively, and the final concentration of the virus was 0.1 MOI.
  • the mixture was transferred to a 96-well plate in which cells were plated, and cultured at 37 ° C, 5% CO 2 for 24 hours, and then the polypeptide was inhibited against the virus by a CCK8 kit.
  • polypeptide inhibition rate (drug well-viral pore) ⁇ 100% / (no drug pore-viral pore).
  • polypeptide P2 modified polypeptide 3A-TAT-EP shown in SEQ ID NO. 3
  • 3A-EP-DRI shown in SEQ ID NO. 4
  • 3A-EP-PEG4- PA shown in SEQ ID NO. 5
  • the IC 50 of 3A-EP-PEG4-PA was determined by qRT-PCR to be 3.25 ⁇ M.
  • FIG. 6 as determined by viral polypeptide CCK8 method showed inhibitory activity, 3A-TAT-EP IC 50 of 4.36 ⁇ M, and 3A-EP-DRI IC 50 of 3.56 ⁇ M.
  • MEM medium (Thermo), serum (Gibco) was purchased from Infineon, Inc., immunofluorescent plate (NEST) was purchased from the promoter company, PBS, DAPI, and paraformaldehyde was purchased from Diyue Innovation Co., Ltd.
  • the polypeptide P1 was synthesized by Nanjing Kingsray Co., Ltd., and its sequence is shown in SEQ ID NO.
  • the experiment was divided into two groups. In order to avoid the influence of the addition of EV71 virus on the entry of the polypeptide into the cells, one group of experiments added EV71 virus and then added the polypeptide P1, and the other group added the virus without adding the virus, and each group was made a negative control.
  • the immunofluorescence steps are as follows:
  • the transmembrane efficiency in RD cells was examined using a fluorescently labeled (FITC) polypeptide.
  • FITC fluorescently labeled
  • Two sets of experiments were set up. The first group was untreated control, R8 was added, P1 was added, and P2 was added. The second group was infected with EV71, infected with EV71 and added with R8, infected with EV71, and added with P1, infected with EV71 and added with P2.
  • CCK-8 Reagent (MCE) was purchased from a startup subsidiary.
  • Peptide P1 not only inhibits the virus in the process of antiviral, but also ensures that it is not toxic to cells. Therefore, this indicator was tested by a cytotoxicity test, and the cells which were not treated were used as a control group.
  • a 96-well cell plate was plated with RD cells at 100 ⁇ l per well.
  • the MEM medium containing 10% serum is replaced with the MEM medium containing 2% serum, and a certain concentration gradient of the polypeptide P1 is added to make the final P1 concentration in the well.
  • concentration gradient of the polypeptide P1 was added to make the final P1 concentration in the well. They were 0.01 ⁇ M, 0.1 ⁇ M, 1 ⁇ M, 10 ⁇ M, and 100 ⁇ M, respectively.
  • the results are shown in Fig. 15 and Table 4.
  • the cell viability of the untreated cells was 100%. After adding 100 ⁇ M of the polypeptide, the cell viability was not significantly different from that of the control group, which proved that the polypeptide P1 used in the study did not have cells within 100 ⁇ M. toxicity.
  • the cytotoxicity of the polypeptide P1 was detected by RD cells.
  • the concentration gradient peptide P1 was added at a concentration of 0 ⁇ M (control group), 0.01 ⁇ M, 0.1 ⁇ M, 1 ⁇ M, 10 ⁇ M, 100 ⁇ M, respectively.
  • Example 8 Determination of cytotoxicity of polypeptide 3A-TAT-EP
  • CCK-8 Reagent (MCE) was purchased from a startup subsidiary.
  • the polypeptide 3A-TAT-EP not only inhibits the virus but also has no toxicity to the cells during the antiviral process. Therefore, this indicator was tested by a cytotoxicity test, and the cells which were not treated were used as a control group.
  • a 96-well cell plate was plated with RD cells at 100 ⁇ l per well.
  • the MEM medium containing 10% serum is replaced with the MEM medium containing 2% serum, and a certain concentration of the polypeptide EP is added to make the final EP concentration in the well.
  • concentration of the polypeptide EP was added to make the final EP concentration in the well. They were 0.01 ⁇ M, 0.1 ⁇ M, 1 ⁇ M, 10 ⁇ M, and 100 ⁇ M, respectively.
  • the results are shown in Fig. 16 and Table 5.
  • the cell viability of the untreated cells was 100%, and there was no significant difference between the cell viability and the control group (untreated cells) after adding 100 ⁇ M of the polypeptide, which proved that the polypeptide used in the study was 3A-TAT.
  • -EP is not toxic to cells within 100 ⁇ M.
  • the cytotoxicity of the polypeptide 3A-TAT-EP was detected by RD cells.
  • the concentration gradient peptide 3A-TAT-EP was added to the 80% confluent RD cells at concentrations of 0.01 ⁇ M, 0.1 ⁇ M, 1 ⁇ M, 10 ⁇ M, and 100 ⁇ M, respectively. Three concentration experiments were set up for each concentration gradient. After 24 hours, the cells were taken and the cell viability was measured using a CCK-8 kit.
  • Example 9 Determination of cytotoxicity of polypeptides 3A-EP-DRI and 3A-EP-PEG4-PA
  • CCK-8 Reagent (MCE) was purchased from a startup subsidiary.
  • the peptides 3A-EP-DRI and 3A-EP-PEG4-PA not only inhibit the virus but also ensure no toxicity to the cells during the antiviral process. Therefore, this indicator was tested by a cytotoxicity test, and the cells which were not treated were used as a control group.
  • a 96-well cell plate was plated with RD cells at 100 ⁇ l per well.
  • the results are shown in Fig. 17 and Table 6.
  • the cell viability of the untreated cells was 100%, and the cell viability was substantially the same as that of the control group (untreated cells) after adding 100 ⁇ M of the polypeptide, which proved that the polypeptide used in the study was 3A-EP-DRI. And 3A-EP-PEG4-PA is not toxic to cells within 50 ⁇ M.
  • the cytotoxicity of the peptides 3A-EP-DRI and 3A-EP-PEG4-PA was detected by RD cells.
  • the concentration gradient peptides EP-DRI and EP-PEG4-PA were added to the RD cells with 80% confluency, respectively. 0.01 ⁇ M, 0.1 ⁇ M, 1 ⁇ M, 10 ⁇ M, 20 ⁇ M, 30 ⁇ M, 40 ⁇ M, 50 ⁇ M. After 24 hours, the cells were taken and the cell viability was measured using a CCK-8 kit. The results showed that the cell viability was consistent with the control group after adding 50 ⁇ M polypeptide, and it was confirmed that the polypeptides 3A-EP-DRI and 3A-EP-PEG4-PA were not toxic to cells within 50 ⁇ M.
  • RNA extraction kit (Omega), 24-well plate, 100mm dish, 50ml syringe were purchased from Diyue Innovation Co., Ltd., 0.22 ⁇ m filter (Millipore) was purchased from the company, and the One step qRT-PCR kit (Takara) was purchased. Since the company, the water used in the extraction of RNA and qRT-PCR was DEPC water, and the whole experiment was carried out in the RNase Free environment.
  • One step qRT-PCR was performed by taking 100 ⁇ l of virus-extracted RNA and previously extracted known titer of viral RNA, and the virus titer was measured.
  • concentration gradient polypeptides EP-PA, EP-CHOL, 3A-EP-DRI and 3A-EP-PEG4-PA were added, respectively, and all polypeptide concentrations were set to 0.01 ⁇ M, 0.1 ⁇ M, 1 ⁇ M, and 10 ⁇ M.
  • the total RNA was extracted, and the expression level of viral genomic RNA was detected by real-time PCR, so that only the sample without the added polypeptide was used as the control group. The results showed that all of the peptides had anti-EV71 activity, and increasing the polypeptide concentration significantly inhibited the expression level of viral RNA.
  • the antiviral effects of the polypeptides P2, ER and ER-DRI were detected by RD cells, and the transmembrane peptides R8 and TAT were used as controls.
  • the inhibitory activity of the polypeptide against the virus was determined using a CCK-8 kit 24 hours after infection.
  • Polypeptide inhibition rate (drug well-viral well) x 100% / (no drug well-viral well).
  • the results showed that the peptides P2, ER and ER-DRI all significantly inhibited CVA16, while the transmembrane peptides R8 and TAT did not contribute to the virus.
  • RRRRRRRRAISDLLAS is a commercial synthesis. Newly born 2 day old ICR suckling rats.
  • one group was intraperitoneally injected with 10 mg/kg of P1 polypeptide as the treatment group, and the other group was injected with the same amount of PBS as the control group.
  • mice were euthanized, and their hind limb muscles were taken and triturated with Trizol to extract total RNA from the tissues.
  • Example 12 Detection of polypeptide CR inhibiting EV71 activity in RD cells
  • the IC 50 of CR for EV71 was 1.7 ⁇ M.
  • Example 13 Antiviral activity of polypeptide CR against EV71 and CVA16 in mice
  • Peptide CR YGRKKRRQRRRGSGCR is a commercial synthesis. Newly born 2 day old ICR suckling rats.
  • mice were euthanized, and their hind limb muscles were taken and triturated with Trizol to extract total RNA from the tissues.
  • the polypeptide ER-DRI is a commercial synthesis of 12 10-day-old suckling mice.
  • mice were randomly divided into two groups, 6 in each group. One group was intraperitoneally injected with 20 mg/kg ER-DRI once a day for 3 consecutive days. Another group was injected with an equal amount of PBS as a control.
  • mice The body weight of the mice was recorded daily for a total of 15 days.
  • mice were euthanized, and the brain, liver, lungs, and kidneys were dissected and separated for HE staining.
  • CCK-8 Reagent (MCE) was purchased from a startup subsidiary.
  • the polypeptide ER and ER-DRI not only inhibit the virus but also ensure no toxicity to the cells during the antiviral process. Therefore, this indicator was tested by a cytotoxicity test, and the cells which were not treated were used as a control group.
  • a 96-well cell plate was plated with RD cells at 100 ⁇ l per well.
  • the cell viability of the untreated cells was 100%
  • the half cytotoxicity (CC 50 ) of TAT-ER-DRI was 117 ⁇ M
  • the half CC 50 of the TAT-ER was calculated to be 290 ⁇ M. It was proved that the polypeptide ER used in this study is a very low toxicity drug compared with the half-cell cytotoxicity (290 ⁇ M, 117 ⁇ M) of ER-DRI, which is half-inhibitory activity (1.26 ⁇ M, 0.64 ⁇ M).
  • Example 16 ER and ER-DRI inhibit EV71 activity detection on RD cells
  • RNA extraction kit (Omega), 24-well plate, 100mm dish, 50ml syringe were purchased from Diyue Innovation Co., Ltd., 0.22 ⁇ m filter (Millipore) was purchased from Hida Co., Ltd., One step q-pcr kit (Takara) was purchased. Since the company, the water used in the extraction of RNA and qRT-PCR was DEPC water, and the whole experiment was carried out in the RNase Free environment.
  • the polypeptide ER-DRI is a commercial synthesis of 10 2 day old suckling mice.
  • mice After the fifth day, the suckling mice were euthanized, their lungs were taken, and the total RNA in the tissues was extracted after grinding with Trizol.
  • ER-DRI significantly reduced the EV71 viral load in the mouse lung.
  • Example 18 Toxicity of polypeptides BP8, BP10 and BP15 in RD cells
  • CCK-8 Reagent (MCE) was purchased from a startup subsidiary.
  • the peptides BP8, BP10 and BP15 not only inhibit the virus but also ensure no toxicity to the cells during the antiviral process. Therefore, this indicator was tested by a cytotoxicity test, and the cells which were not treated were used as a control group.
  • a 96-well cell plate was plated with RD cells at 100 ⁇ l per well.
  • the MEM medium containing 10% serum is replaced with MEM medium containing 2% serum, and a certain concentration gradient of polypeptide polypeptides BP8, BP10 and BP15 is added to make the pores
  • the final concentrations in the medium were 3.0625 ⁇ M, 6.125 M, 12.5 ⁇ M, 25 ⁇ M, 50 ⁇ M, 100 ⁇ M, and 200 ⁇ M, respectively.
  • the results are shown in Fig. 23 and Tables 27, 28 and 29.
  • the cell viability of the untreated cells was 100%.
  • the cell viability of BP8 and BP10 after adding 200 ⁇ M polypeptide was basically the same as that of the control group (untreated cells), and BP15 was added with 100 ⁇ M polypeptide.
  • the post-cell viability was basically consistent with the control group (untreated cells), and the viability decreased to 20% after the addition of 200 ⁇ M polypeptide. It indicated that BP8 and BP10 were not toxic to cells within 200 ⁇ M, and BP15 was not toxic to cells within 100 ⁇ M.
  • CCK-8 Reagent (MCE) was purchased from a startup subsidiary.
  • the peptides BP8, BP10 and BP15 not only inhibit the virus but also ensure no toxicity to the cells during the antiviral process. Therefore, this indicator was tested by a cytotoxicity test, and the cells which were not treated were used as a control group.
  • the MEM medium containing 10% serum is replaced with MEM medium containing 2% serum, and a certain concentration gradient of polypeptide polypeptides BP8, BP10 and BP15 is added to make the pores
  • the final concentrations in the medium were 3.0625 ⁇ M, 6.125 M, 12.5 ⁇ M, 25 ⁇ M, 50 ⁇ M, 100 ⁇ M, and 200 ⁇ M, respectively.
  • the results are shown in Fig. 24 and Tables 30, 31 and 32.
  • the cell viability of the untreated cells was 100%.
  • the cell viability of BP8 and BP10 after adding 200 ⁇ M polypeptide was basically the same as that of the control group (untreated cells), and BP15 was added with 100 ⁇ M polypeptide.
  • the post-cell viability was basically the same as that of the control group (untreated cells), and the viability decreased to 20% after the addition of 200 ⁇ M of the polypeptide. It indicated that BP8 and BP10 were not toxic to cells within 200 ⁇ M, and BP15 was not toxic to cells within 100 ⁇ M. The toxicity of the drug in RD cells and Vero cells is relatively consistent.
  • Polypeptides BP8 (shown as SEQ ID NO. 12), BP10 (shown as SEQ ID NO. 13), and BP15 (shown as SEQ ID NO. 14). The sequences are all commercially synthesized.
  • a 24-well plate was plated with RD cells.
  • polypeptides BP8, BP10 and BP15 were all able to significantly inhibit CVB5.
  • IC50 BP15 was 6.758 ⁇ M.
  • polypeptide BP8 shown in SEQ ID NO. 12
  • sequences described for polypeptide BP8 are all commercially synthesized.
  • a 24-well plate was plated with Vero cells.
  • polypeptide BP8 at a final concentration of 2.5 ⁇ M, 5 ⁇ M, and 10 ⁇ M was added, respectively.
  • polypeptide BP8 was able to inhibit the replication of CVB3.
  • BP8 an IC 50 of 4.125 ⁇ M ..
  • Polypeptide BP8 (shown as SEQ ID NO. 12) is a commercial synthesis. Newly born 2 day old ICR suckling rats.
  • mice After the fifth day, the suckling mice were euthanized, and their hind limb muscles were taken and ground with Rrizol to extract total RNA from the tissues.
  • the virion copy number of the medicated group (PB10) was significantly lower than that of the blank control group (PBS), and the virion decreased by nearly 80 times.
  • sequences described in the polypeptide ER-DEI (SEQ ID No. 11) are all commercially synthesized.
  • a 24-well plate was plated with Vero cells.
  • polypeptide BP8 at a final concentration of 2.5 ⁇ M, 5 ⁇ M, and 10 ⁇ M was added, respectively.
  • the polypeptide ER-DEI was able to inhibit the replication of CVA6.
  • BP8 less than the IC 50 0.625 ⁇ M.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PCT/CN2019/072455 2018-01-20 2019-01-21 一种广谱抗肠道病毒的多肽及其应用 WO2019141263A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2020560535A JP7252575B2 (ja) 2018-01-20 2019-01-21 広域エンテロウイルス抵抗性ポリペプチド及びその応用
US16/963,196 US11999806B2 (en) 2018-01-20 2019-01-21 Broad-spectrum polypeptide against enterovirus and application thereof
CN201980005805.6A CN112261946B (zh) 2018-01-20 2019-01-21 一种广谱抗肠道病毒的多肽及其应用
AU2019208788A AU2019208788B2 (en) 2018-01-20 2019-01-21 “Broad-spectrum polypeptide against Enterovirus and application thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810056297.1A CN110064044B (zh) 2018-01-20 2018-01-20 一种肠道病毒71型的抑制剂及应用
CN201810056297.1 2018-01-20

Publications (1)

Publication Number Publication Date
WO2019141263A1 true WO2019141263A1 (zh) 2019-07-25

Family

ID=67301298

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/072455 WO2019141263A1 (zh) 2018-01-20 2019-01-21 一种广谱抗肠道病毒的多肽及其应用

Country Status (5)

Country Link
US (1) US11999806B2 (ja)
JP (1) JP7252575B2 (ja)
CN (2) CN110064044B (ja)
AU (1) AU2019208788B2 (ja)
WO (1) WO2019141263A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110064044B (zh) * 2018-01-20 2022-09-09 中国科学院武汉病毒研究所 一种肠道病毒71型的抑制剂及应用
CN113999286B (zh) * 2020-07-28 2024-08-02 中国科学院武汉病毒研究所 一种靶向肠道病毒2c蛋白的广谱抗肠道病毒的多肽抑制剂及应用
CN114989294A (zh) * 2022-05-27 2022-09-02 中国科学院武汉病毒研究所 一种抗ev71病毒抗体及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105394045A (zh) * 2014-09-04 2016-03-16 中国科学院上海巴斯德研究所 一种肠道病毒的小分子化合物抑制剂及其应用
CN105518128A (zh) * 2013-07-16 2016-04-20 迪特桑有限公司 遗传稳定的溶瘤性rna病毒、其制备方法及用途
CN106668832A (zh) * 2017-03-30 2017-05-17 江苏吉锐生物技术有限公司 一种多肽在制备治疗肠道病毒感染药物的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103301462B (zh) * 2012-03-09 2015-06-03 海南康芝药业股份有限公司 治疗病毒疾病的成分和方法
US10328128B2 (en) * 2014-09-17 2019-06-25 Ansun Biopharma, Inc. Treatment of infection by human enterovirus D68
CN110064044B (zh) * 2018-01-20 2022-09-09 中国科学院武汉病毒研究所 一种肠道病毒71型的抑制剂及应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105518128A (zh) * 2013-07-16 2016-04-20 迪特桑有限公司 遗传稳定的溶瘤性rna病毒、其制备方法及用途
CN105394045A (zh) * 2014-09-04 2016-03-16 中国科学院上海巴斯德研究所 一种肠道病毒的小分子化合物抑制剂及其应用
CN106668832A (zh) * 2017-03-30 2017-05-17 江苏吉锐生物技术有限公司 一种多肽在制备治疗肠道病毒感染药物的应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE Protein 6 November 2017 (2017-11-06), "polyprotein [Coxsackievirus A6]", XP055628805, retrieved from NCBI Database accession no. ATP75734.1 *
GAO, Q. Q. ET AL.: "Discovery of Itraconazole with Broad-Spectrum in Vitro Antienterovirus Activity that Targets Nonstructural Protein 3A", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 59, no. 5, 31 May 2015 (2015-05-31), pages 2654 - 2665, XP055628810 *
GONZALEZ-MAGALDI, M. ET AL.: "Peptides Interfering 3A Protein Dimerization Decrease FMDV Multiplication", PLOS ONE, vol. 10, no. 10, 27 October 2015 (2015-10-27), pages e0141415, XP055628800 *
TANG, RUI ET AL.: "Screening Protein Interacted with Enterovirus 71 3A Protein by means of T7-phage Display System", INTERNATIONAL JOURNAL OF LABORATORY MEDICINE, vol. 35, no. 16, 31 August 2014 (2014-08-31), pages 2129 - 2131, XP055628809 *
ZHANG, XIAOKANG ET AL.: "Advances in Research on Anti-intestinal Virus Target Drugs", CHINESE MEDICINAL BIOTECHNOLOGY, vol. 11, no. 5, 30 October 2016 (2016-10-30), pages 451 - 456 *

Also Published As

Publication number Publication date
CN112261946A (zh) 2021-01-22
AU2019208788A1 (en) 2020-09-10
US11999806B2 (en) 2024-06-04
AU2019208788B2 (en) 2023-10-19
CN110064044A (zh) 2019-07-30
CN112261946B (zh) 2024-08-30
CN110064044B (zh) 2022-09-09
JP2021512642A (ja) 2021-05-20
JP7252575B2 (ja) 2023-04-05
US20230192769A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
Yi et al. Enterovirus 71 infection and vaccines
Wang et al. Enterovirus A71 antivirals: past, present, and future
Shang et al. Antiviral drug discovery for the treatment of enterovirus 71 infections
Wu et al. Developments towards antiviral therapies against enterovirus 71
WO2019141263A1 (zh) 一种广谱抗肠道病毒的多肽及其应用
JP2023513436A (ja) ２０１９新型コロナウイルス（２０１９－ｎＣｏＶ）によって引き起こされる重症急性呼吸器感染症の治療のためのＲＮＡｉ予防治療薬組成物及び方法
Fang et al. Inhibition of viral suppressor of RNAi proteins by designer peptides protects from enteroviral infection in vivo
Kinobe et al. Insight into the Enterovirus A71: A review
Wang et al. Advances in anti-EV-A71 drug development research
US20230295236A1 (en) Compounds for use in inflammatory conditions
Sakr et al. Latest updates on SARS-CoV-2 genomic characterization, drug, and vaccine development; a comprehensive bioinformatics review
Makhluf et al. Innate antiviral immunity against dengue virus
JP2009221131A (ja) Ｃ型肝炎ウイルス阻害剤
JP2023535570A (ja) エンテロウイルスに対する広域スペクトル抗ウイルス薬及びその応用
Gazina et al. Viral targets of acylguanidines
CN111317739A (zh) 依托红霉素在制备特异性抑制病毒感染的药物中的用途
CN110693896B (zh) 一种肠道病毒小分子抑制剂及其应用
Kheshtchin et al. Immunoediting in SARS-CoV-2: Mutual relationship between the virus and the host
Ortiz et al. New Drugs in Synthesis Research for Viral Diseases
CN112794807B (zh) 九氨胍及其制备方法和防治冠状病毒感染的应用
Getso et al. Therapeutic strategies for COVID-19 patients: An update
EP2683369A1 (en) Multiantivirus compound, composition and method for treatment of virus diseases
LOCHAIYAKUN et al. Screening drug libraries to discover virus-directed or host-directed therapy for EV-A71 infection
Men Genetic Epidemiology and Molecular Interaction with Host Cell Proteins of EV-A71
Castillo et al. Myeloid Cell Reservoirs: Role in HIV-Host Interplay and Strategies for Myeloid Reservoir Elimination

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19741010

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020560535

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019208788

Country of ref document: AU

Date of ref document: 20190121

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 19741010

Country of ref document: EP

Kind code of ref document: A1